A novel targeted anti-cancer therapy with immunotoxin and cyclosporin - Clinical and translational studies
- Prosjektnummer
- 2009091
- Ansvarlig person
- Øystein Fodstad
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Postdoktorstipend
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.
PLoS One 2011;6(9):e24012. Epub 2011 sep 7
PMID: 21915275
Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins.
J Immunother 2011 Jun;34(5):438-47.
PMID: 21577141
Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells.
J Immunother 2010 Apr;33(3):272-8.
PMID: 20445347
Immunotoxins in Targeted Cancer Therapy
Annual GAP conference, 2012, Oslo
Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma possibly involves silencing of the anti-apopt
Annual GAP conference, 2012, Oslo
Immunotoxin Therapy of Peritoneal Surface Malignancies - Preclinical studies.
Fabisch-Symposium for Cancer Research and Molecular Cell Biology. 3RD Targeted
Immunotoxins: A Promising Treatment Modality for Metastatic Melanoma?
The Oshner Journal
Synergistic anti-cancer effect of immunotoxins & triphenylmethyl -derivates involves decreased stearoyl-CoA desaturase protein l
Konferense,18th ECDO
Synergistic anti-cancer effect of immunotoxins and triphenylmethyl-derivates involves decreased stearoyl-CoA desaturase protein
Konferense, Keystone
PhD
- Disputert:
- mai 2010
- Hovedveileder:
- Yvonne Andersson
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport